{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:47:08Z","timestamp":1767916028621,"version":"3.49.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1704","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Eohilia (Takeda), an oral suspension formulation of the corticosteroid budesonide, has been approved by the FDA for treatment of eosinophilic esophagitis (EoE) in patients \u226511 years old. It is the first oral drug to be approved in the US for this indication. The subcutaneously injected interleukin (IL)-4 receptor antagonist dupilumab (Dupixent) is approved for treatment of EoE in patients \u22651 year old who weigh \u226515 kg.<\/jats:p>","DOI":"10.58347\/tml.2024.1704c","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T22:05:01Z","timestamp":1718661901000},"page":"93-95","source":"Crossref","is-referenced-by-count":1,"title":["Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis"],"prefix":"10.58347","volume":"66","member":"37151","published-online":{"date-parts":[[2024,6,10]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T22:05:01Z","timestamp":1718661901000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1704c"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":0,"journal-issue":{"issue":"1704","published-online":{"date-parts":[[2024,6,10]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1704c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]}}}